Reports Q2 revenue $104.6M, consensus $104.08M. “Our commercial team has continued to field significant interest from customers seeking to expand their use of model-informed drug development,” said William Feehery, CEO. “We are excited about software product enhancements and new product introductions that will expand our market leading offering and deliver sustainable long-term growth.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara announces EMA qualification of Simcyp Simulator
- Certara appoints Christopher Bouton as CTO
- Certara expands clinical technology collaboration with Merck
- Certara assumed with an Equal Weight at Morgan Stanley
- Certara’s Steady Growth Amid Strategic and Regulatory Uncertainties: A Hold Rating Analysis